Cullinan Therapeutics, Inc. (CGEM) · Sep 14, 2026 · Other events

Cullinan’s zipalertinib cuts progression risk in Phase 3, but OS remains immature

Above the bar — Median PFS 14.5 vs 8.5 months; HR 0.50

Cullinan’s partnered lung-cancer drug posts a substantial Phase 3 PFS benefit, strengthening the regulatory case while overall survival remains unproven.

The market already knew the trial had succeeded, but not the size of the win. Cullinan’s current story is a transition from a broad clinical portfolio toward a more consequential phase: partnered zipalertinib is the nearer-term regulatory asset, while its T-cell engagers remain earlier-stage value drivers. The filing confirms that REZILIENT3 had met its primary endpoint, but the full interim dataset is the new information. 〔0〕

MeasureZipalertinib + chemotherapyChemotherapy aloneRead-through
Median PFS14.5 months8.5 months6.0-month advantage (Summary of Results)
PFS hazard ratio0.50—50% lower progression or death risk (Summary of Results)
Objective response rate65.0%40.3%24.7-point advantage (Summary of Results)
Median duration of response14.2 months9.9 months4.3-month advantage (Summary of Results)
Overall-survival hazard ratio0.72—Directionally favorable, but only 30% mature (Summary of Results)
Grade ≥3 adverse events87.1%54.4%Meaningfully higher toxicity burden (Summary of Preliminary Safety and Tolerability)

The efficacy result is clearly above the clinical success bar. A median PFS improvement from 8.5 to 14.5 months, a hazard ratio of 0.50, higher response rates and longer response duration together make this more than a narrow endpoint win. The benefit also extended to patients with brain metastases, an important subgroup for first-line EGFR-mutated lung cancer. 〔1〕

The main limitation is that the regulatory-quality efficacy signal is stronger than the survival evidence so far. Overall survival points in the right direction, but the hazard ratio’s confidence interval crosses 1.0 and the analysis is only 30% mature. That leaves follow-up and regulatory execution as the remaining steps before this becomes a fully de-risked commercial opportunity.

Safety is a real trade-off, not a reason to overturn the read. Severe adverse events were substantially more common with the combination, driven mainly by hematologic toxicity, although the filing reports no new safety signals and characterizes the profile as generally consistent with the individual agents. Net: this materially advances Cullinan’s partnered-asset narrative from “promising Phase 3 success” to “strong first-line efficacy with a plausible regulatory path,” while leaving overall-survival maturity and treatment tolerability as the key remaining questions. 〔2〕

What to watch next

Regulatory discussions with health authorities

Original filing on SEC EDGAR

More Cullinan Therapeutics, Inc. news

Cullinan’s zipalertinib cuts progression risk in Phase 3, but OS remains immature | CGEM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.